Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas

Cancer Genetics and Cytogenetics

Volumn 144, Issue 2, 2003, Pages 134-142

  Alonso, M Eva ^a   Bello, M Josefa ^a   Gonzalez Gomez, Pilar ^a   Arjona, Dolores ^a   Lomas, Jesus ^a   De Campos, Jose M ^b   Isla, Alberto ^a   Sarasa, Jose L ^c   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CPG ISLAND; EPENDYMOMA; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; METHYLATION; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0037678573     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00928-7     Document Type: Article

References (50)

1. Kleihues P., Cavenee W.K. Pathology and genetics of tumors of the nervous system. World Health Organization classification of tumors. 2000;IARC Press, Lyon.
2. Cairncross J.G., Ueki K., Zlatescu C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A., Louis D.N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 90:1998;1473-1479.
3. Ino Y., Zlatescu M.C., Sasaki H., Macdonald D.R., Stemmer-Rachamimov A.O., Jhung S., Ramsay D.A., von Deimling A., Louis D.N., Cairncross J.G. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 92:2000;983-990.
4. Ino Y., Betensky R.A., Zlatescu M.C., Sasaki H., Macdonald D.R., Stemmer-Rachamimov A.O., Ramsay D.A., Cairncross J.G., Louis D.N. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 7:2001;839-845.
5. Smith J.S., Perry A., Borell T.J., Lee H.K., O'Fallon J., Hosek S.M., Kimmel D., Yates A., Burger P.C., Scheithauer B.W., Jenkins R.B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 18:2000;636-645.
6. Alonso M.E., Bello M.J., Arjona D., Gonzalez-Gomez P., Lomas J., de Campos J.M., Kusak M.E., Isla A., Rey J.A. Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 134:2002;1-5.
7. Ebert C., von Haken M., Meyer-Puttlitz B., Wiestler O.D., Reifenberger G., Pietsch T., von Deimling A. Molecular analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol. 155:1999;627-632.
8. Hulsebos T.J.M., Oskam N.T., Bijleveld E.H., Westerveld A., Hermsen M.A., van den Ouweland A.M.W., Hamel B.C., Tijssen C.C. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. Br J Cancer. 81:1999;1150-1154.
9. Tong C.Y.-K., Zheng P.-P., Pang J.C.-S., Poon W.-S., Chang A.R., Ng H.-K. Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 348 microsatellite markers. J Neurosurg. 95:2001;9-14.
10. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72:1998;141-196.
11. Delgado S., Gomez M., Bird A., Antequera F. Initiation of DNA replication at CpG islands in mammalian chromosomes. EMBO J. 17:1998;2426-2435.
12. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat Genet. 21:1999;163-167.
13. Watanabe T., Yokoo H., Yokoo M., Yonekawa Y., Kleihues P., Ohgaki H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol. 60:2001;1181-1189.
14. Bortolotto S., Chiado-Piat L., Cavalla P., Bosone I., Chio A., Mauro A., Schiffer D. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer. 88:2000;554-557.
15. Dong S.-M., Pang J.C.-S., Poon W.-S., Hu J., Yo K.-F., Chang A.R., Ng H.-K. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol. 60:2001;808-816.
16. INK4a genes in oligodendrogliomas. Acta Neuropathol (Berl). 101:2001;185-189.
17. INK4b) tumor suppressor genes. J Neuropathol Exp Neurol. 60:2001;1170-1180.
18. Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusak M.E., Sarasa J.L., Pestaña A., Rey J.A. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer. 64:1995;207-210.
19. Alonso M.E., Bello M.J., Gonzalez-Gomez P., Lomas J., Arjona D., de Campos J.M., Kusak M.E., Sarasa J.L., Isal A., Rey J.A. Mutation analysis of the p73 gene in nonastrocytic brain tumors. Br J Cancer. 85:2001;204-208.
20. Bello M.J., de Campos J.M., Vaquero J., Ruiz-Barnes P., Kusak M.E., Sarasa J.L., Rey J.A. HRAD54 gene and 1p high-resolution deletion-mapping analyses in oligodendrogliomas. Cancer Genet Cytogenet. 116:2000;142-147.
21. Rey J.A., Bello M.J., Jimenez-Lara A., Vaquero J., Kusak M.E., de Campos J.M., Sarasa J.L., Pestaña A. Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer. 51:1992;703-706.
22. Leone P.E., Bello M.J., de Campos J.M., Vaquero J., Sarasa J.L., Pestaña A., Rey J.A. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene. 18:1999;2231-2239.
23. Yoshikawa H., Nagashima M., Khan M.A., McMenamin M.G., Hagiwara K., Harris C.C. Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene. 18:1999;3415-3421.
24. Ohgaki H., Eibl R.H., Wiestler O.D., Yasargil M.G., Newcomb E.W. Kleihues P. p53 Mutations in nonastrocytic human brain tumors. Cancer Res. 51:1991;6202-6205.
25. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 93:1996;9821-9826.
26. Corn P.G., Kuerbitz S.J., van Noesel M.M., Esteller M., Compitello N., Baylin S.B., Herman J.G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 59:1999;3352-3356.
27. Frühwald M.C., O'Dorisio M.S., Dai Z., Tanner S.M., Balster D.A., Gao X., Wright F.A., Plass C. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas: implications for tumor biology and potential clinical utility. Oncogene. 20:2001;5033-5042.
28. Kang G.H., Shim Y.-H., Jung H.-Y., Kim W.H., Ro J.Y., Rhyu M.-G. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res. 61:2001;2847-2851.
29. Simpson D.J., Hibberts N.A., McNicol A.M., Clayton R.N., Farrell W.E. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 60:2000;1211-1216.
30. INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 5:1999;2704-2713.
31. Zöchbauer-Müller S., Fong K.M., Virmani A.K., Geradts J., Gazdar A.F., Minna J.D. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61:2001;249-255.
32. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:1999;793-797.
33. Fink K.L., Rushing E.J., Schold S.C., Nisen P.D. Infrequency of p53 gene mutations in ependymomas. J Neurooncol. 27:1996;111-115.
34. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:2000;1350-1354.
35. Nutt C.L., Noble M., Chambers A.F., Cairncross J.G. Differential expression of the drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response to oligodendrogliomas and astrocytomas chemotherapy. Cancer Res. 60:2000;4812-4818.
36. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 61:2001;4689-4692.
37. Daniel V. Glutathione S-transferases: gene structure and regulation of expression. Crit Rev Biochem Mol Biol. 28:1993;173-207.
38. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
39. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M., Jen J., Herman J.G., Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60:2000;892-895.
40. Li Q., Ahuja N., Burger P.C., Issa J.-P.J. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene. 18:1999;3284-3289.
41. Roberts D.D. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. 10:1996;1183-1191.
42. Del Maestro R.F. Angiogenesis. Berger M.S., Wilson C.B. The gliomas. 1999;87-106 WB Saunders, Philadelphia.
43. Dong S., Pang J.C., Hu J., Zhou L., Ng H. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer. 98:2002;370-375.
44. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., Baylin S.B., Graff J.R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59:1999;798-802.
45. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1997;1260-1270.
46. Jubb A.M., Bell S.M., Quirke P. Methylation and colorectal cancer. J Pathol. 195:2001;111-134.
47. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
48. Robertson K.D., Jones P.A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 18:1998;6457-6473.
49. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1378:1998;F115-F177.
50. Gonzalez-Gomez P., Bello M.J., Alonso M.E., Arjona D., Lomas J., de Campos J.M., Isala A., Rey J.A. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer. 2003;. In press.